

**Ycanth (cantharidin)**  
**Effective 10/01/25**

<b>Plan</b>	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange		<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization
<b>Benefit</b>	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit			<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Specialty Limitations</b>	N/A			
<b>Contact Information</b>	<b>Medical Benefit</b> <b>Pharmacy Benefit</b>		Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
<b>Exceptions</b>	N/A			

**Overview**

Ycanth (cantharidin) is the first FDA-approved treatment for molluscum contagiosum for adults and children 2 years of age and older.

**Coverage Guidelines**

Authorization may be granted for members when all the following criteria are met:

- Diagnosis of molluscum contagiosum and **ONE** of the following:
  - itching, pain, or bleeding associated with lesions
  - member is immunocompromised
  - concomitant atopic dermatitis
  - concomitant bacterial infection
  - risk of spread to contacts (i.e., siblings, daycare)
- Member is  $\geq 2$  years of age
- Inadequate response or adverse reaction to **ONE** or contraindication to **ALL** of the following:
  - podofilox
  - cryotherapy
  - curettage
  - potassium hydroxide
  - salicylic acid
  - topical retinoid (i.e., adapalene, tazarotene, tretinoin)
- Requested dose is  $\leq 8$  applicators/12 weeks

**Continuation of Therapy**

Reauthorization when prescriber provides documentation of medical necessity for use beyond 12 weeks.

**Limitations**

- Initial approvals and reauthorizations will be granted for up to 12 weeks.

**References**

- Ycanth [package insert]. West Chester (PA): Verrica Pharmaceuticals Inc.; 2024 Nov.

2. FDA approves first treatment for molluscum contagiosum [press release on the internet]. FDA; 2023 Jul 24 [cited 2023 Nov 15]. Available from: <https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-molluscum-contagiosum>.
3. Isaacs SN. Molluscum contagiosum. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2023 [cited 2023 Nov 15]. Available from: <http://www.utdol.com/utd/index.do>.

### **Review History**

2/14/24 – Created for P&T. Adopted MH criteria. Ycanth will require PA on MB. Effective 3/4/24

05/15/25 – Reviewed and updated for P&T. Updated formatting and references. Removed prescriber specialty requirement, matching MH. Effective 6/1/25

9/10/25 – Reviewed and updated for P&T. Updated criteria for Ycanth to include other topical alternatives, potassium hydroxide, salicylic acid and topical retinoid. Added concomitant atopic dermatitis as an acceptable diagnosis. Effective 10/1/25

